Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hüllein

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Scientific Reports|August 15, 2018
Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphomaK Tomska, R Kurilov, K S Lee, et al.
Leukemia|May 15, 2015
p53-dependent non-coding RNA networks in chronic lymphocytic leukemiaC J Blume, A Hotz-Wagenblatt, J Hüllein, et al.
Leukemia|November 6, 2014
The impact of SF3B1 mutations in CLL on the DNA-damage responseG D Te Raa, I A M Derks, V Navrkalova, et al.
Leukemia|August 26, 2016
Dissection of CD20 regulation in lymphoma using RNAiM Słabicki, K S Lee, A Jethwa, et al.
ESMO Open|July 8, 2025
CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trialM-V Teleanu, C E Heilig, S Pirmann, et al.
ESMO Open|November 22, 2021
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trialC E Heilig, P Horak, S Kreutzfeldt, et al.
ESMO Open|April 2, 2025
Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesotheliomaL Möhrmann, M Werner, M Oleś, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2022
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancersA Jahn, A Rump, T J Widmann, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Scientific Reports|August 15, 2018
Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphomaK Tomska, R Kurilov, K S Lee, et al.
Leukemia|May 15, 2015
p53-dependent non-coding RNA networks in chronic lymphocytic leukemiaC J Blume, A Hotz-Wagenblatt, J Hüllein, et al.
Leukemia|November 6, 2014
The impact of SF3B1 mutations in CLL on the DNA-damage responseG D Te Raa, I A M Derks, V Navrkalova, et al.
Leukemia|August 26, 2016
Dissection of CD20 regulation in lymphoma using RNAiM Słabicki, K S Lee, A Jethwa, et al.
ESMO Open|July 8, 2025
CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trialM-V Teleanu, C E Heilig, S Pirmann, et al.
ESMO Open|November 22, 2021
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trialC E Heilig, P Horak, S Kreutzfeldt, et al.
ESMO Open|April 2, 2025
Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesotheliomaL Möhrmann, M Werner, M Oleś, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2022
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancersA Jahn, A Rump, T J Widmann, et al.
Pageof 1